1190307-88-0 | Sofosbuvir

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$93.00	$65.00
1g	95%	in stock	$140.00	$98.00
5g	95%	in stock	$356.00	$249.00
10g	95%	in stock	$558.00	$391.00
25g	95%	in stock	$1,132.00	$793.00

Description

• Catalog Number: AA32325
• Chemical Name: Sofosbuvir
• CAS Number: 1190307-88-0
• Molecular Formula: C22H29FN3O9P
• Molecular Weight: 529.4525
• MDL Number: MFCD18782704
• SMILES: CC(OC(=O)[C@@H](N[P@@](=O)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)F)n1ccc(=O)[nH]c1=O)C)C

Computed Properties

• Complexity: 913
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 11
• XLogP3: 1

Literature

• Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

  Drugs 20170701

• Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

  The New England journal of medicine 20170601

• In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.

  Antiviral therapy 20170101

• Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.

  The Annals of pharmacotherapy 20160101

• Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.

  Journal of virus eradication 20160101

• Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.

  Viruses 20151001

• Interferon-free therapy for hepatitis C: The hurdles amid a golden era.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901

• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

  The New England journal of medicine 20150820

• Hepatitis C virus: Virology, diagnosis and treatment.

  World journal of hepatology 20150608

• Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.

  Clinical therapeutics 20150501

• Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.

  Expert opinion on pharmacotherapy 20150401

• Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.

  Drugs 20150401

• Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

  Lancet (London, England) 20150321

• Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

  JAMA 20150301

• An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

  Canadian journal of gastroenterology & hepatology 20150101

• Changing the face of hepatitis C management - the design and development of sofosbuvir.

  Drug design, development and therapy 20150101

• Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.

  BMC gastroenterology 20150101

• Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

  Antimicrobial agents and chemotherapy 20140701

• The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

  Antimicrobial agents and chemotherapy 20140601

• Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.

  Antimicrobial agents and chemotherapy 20140501

• Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.

  Journal of medicinal chemistry 20140313

• Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.

  Hepatology (Baltimore, Md.) 20140201

• Sofosbuvir for the treatment of hepatitis C virus.

  Expert opinion on pharmacotherapy 20140101

• Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.

  Antimicrobial agents and chemotherapy 20130301

• Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.

  Antimicrobial agents and chemotherapy 20120601

• Interferon free hepatitis C treatment regimens: the beginning of another era.

  Current gastroenterology reports 20120201

• Treatment of chronic hepatitis C--are interferons really necessary?

  Liver international : official journal of the International Association for the Study of the Liver 20120201

• What's new in HCV genotype 2 treatment.

  Liver international : official journal of the International Association for the Study of the Liver 20120201

• Trial watch: an all-oral and interferon-free future for HCV therapy?

  Nature reviews. Drug discovery 20111201

• Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.

  Nucleosides, nucleotides & nucleic acids 20111101

• Synthesis of diastereomerically pure nucleotide phosphoramidates.

  The Journal of organic chemistry 20111021

• The HCV NS5B nucleoside and non-nucleoside inhibitors.

  Clinics in liver disease 20110801

• Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.

  The Journal of biological chemistry 20101105

• Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

  Journal of medicinal chemistry 20101014

• Genetic diversity and evolution of hepatitis C virus--15 years on.

  The Journal of general virology 20041101

• Side effects of alpha interferon in chronic hepatitis C.

  Hepatology (Baltimore, Md.) 19970901